Obalon Announces Upcoming Conference Presentation
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang, President and Chief Operating Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will participate in the following upcoming investor conference:
Canaccord Genuity 38th Annual Growth Conference
Thursday, August 9, 2018, Presentation at 9:00am ETInterContinental Hotel, Boston, MAWebcast Available at: http://wsw.com/webcast/canaccord30/obln/
Live audio webcasts of the presentation can be accessed through the link above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc. Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit http://www.obalon.com/.
For Obalon Therapeutics, Inc.
Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 email@example.com
Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 firstname.lastname@example.org